Compare KRUS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | CABA |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.8M | 495.7M |
| IPO Year | 2019 | 2019 |
| Metric | KRUS | CABA |
|---|---|---|
| Price | $57.52 | $3.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $81.11 | $14.50 |
| AVG Volume (30 Days) | 453.4K | ★ 5.4M |
| Earning Date | 04-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.75 | 10.26 |
| EPS | N/A | N/A |
| Revenue | ★ $282,763,000.00 | N/A |
| Revenue This Year | $20.50 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $42.62 | $1.26 |
| 52 Week High | $95.98 | $4.23 |
| Indicator | KRUS | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 48.87 |
| Support Level | $53.62 | $3.12 |
| Resistance Level | $64.22 | $3.34 |
| Average True Range (ATR) | 3.33 | 0.21 |
| MACD | 1.27 | 0.02 |
| Stochastic Oscillator | 79.65 | 69.61 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.